Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company’s commitment to employee development and growth. <\/p>\n
Neha Jangale, with her extensive experience in the field of human resources, will be responsible for designing and implementing comprehensive learning and development programs across the organization. Her primary focus will be on creating a culture of continuous learning, enabling employees to acquire new skills, and enhancing their overall performance.<\/p>\n
In her new role, Neha will work closely with the leadership team to identify skill gaps and develop targeted training programs to address these gaps. She will also be responsible for creating a robust framework for leadership development, succession planning, and talent management. Her expertise will help in creating a learning ecosystem that supports the company’s business objectives and fosters a culture of innovation and excellence.<\/p>\n
Neha’s appointment is a testament to Glenmark’s commitment to investing in its employees and creating a work environment that encourages growth and development. The company recognizes that its employees are its most valuable assets and is dedicated to providing them with the necessary tools and resources to succeed.<\/p>\n
Glenmark Pharmaceuticals has a strong track record of developing and implementing innovative L&D programs. The company has a dedicated L&D team that works closely with various stakeholders to design and deliver programs that cater to the diverse needs of its employees. With Neha at the helm, the company is expected to take its L&D initiatives to the next level, focusing on creating a more agile, adaptable, and future-ready workforce.<\/p>\n
The appointment of Neha Jangale as the Head of L&D is a significant step forward for Glenmark Pharmaceuticals. Under her leadership, the company is poised to create a learning culture that is aligned with its business strategy and supports the growth and development of its employees. As the pharmaceutical industry continues to evolve, Glenmark is well-positioned to stay ahead of the curve, driven by a talented and skilled workforce. With Neha’s expertise and passion for L&D, the company is expected to achieve its vision of becoming a leading global pharmaceutical company.<\/p>\n","protected":false},"excerpt":{"rendered":"
Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company’s commitment to employee development and growth. Neha Jangale, with her extensive experience in the field of human resources, will be responsible for designing and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23,2],"tags":[],"class_list":["post-89851","post","type-post","status-publish","format-standard","hentry","category-glenmark","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89851,"position":0},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89863,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/glenmark-introduces-emergency-epinephrine-injection-drug-store-news\/","url_meta":{"origin":89851,"position":1},"title":"Glenmark introduces emergency epinephrine injection – Drug Store News","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis. The medication is available in\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89820,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/18\/mankind-pharma-launches-cutting-edge-digital-classrooms-bolstering-community-centric-education-through-kindcare-initiative-as-reported-by-india-education-diary\/","url_meta":{"origin":89851,"position":2},"title":"Mankind Pharma launches cutting-edge digital classrooms, bolstering community-centric education through KindCare initiative, as reported by India Education Diary.","author":"Team Small News","date":"January 18, 2026","format":false,"excerpt":"Mankind Pharma, a leading pharmaceutical company, has launched digital smart classrooms as part of its KindCare initiative, aiming to revolutionize community-first education in India. The inauguration of these state-of-the-art classrooms marks a significant milestone in the company's efforts to bridge the educational gap and provide quality learning opportunities to underprivileged\u2026","rel":"","context":"In "Mankind"","block_context":{"text":"Mankind","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/mankind\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89823,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/mankind-pharma-launches-digital-smart-classrooms-initiative-in-ghaziabad-as-part-of-its-kindcare-corporate-social-responsibility-program\/","url_meta":{"origin":89851,"position":3},"title":"Mankind Pharma launches digital smart classrooms initiative in Ghaziabad as part of its KindCare corporate social responsibility program.","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Mankind Pharma, a leading Indian pharmaceutical company, has launched a digital smart classroom initiative in Ghaziabad as part of its corporate social responsibility (CSR) program, KindCare. The initiative aims to provide quality education to underprivileged students and bridge the digital divide in the region. The company has set up modern\u2026","rel":"","context":"In "Mankind"","block_context":{"text":"Mankind","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/mankind\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89824,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/biocon-expects-robust-q3-performance-fueled-by-biosimilar-growth\/","url_meta":{"origin":89851,"position":4},"title":"Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company's biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89810,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/will-indian-pharmaceuticals-domestic-offerings-provide-a-buffer-against-pricing-pressures-from-the-us-market-in-the-third-quarter\/","url_meta":{"origin":89851,"position":5},"title":"Will Indian pharmaceuticals’ domestic offerings provide a buffer against pricing pressures from the US market in the third quarter?","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to have a mixed third quarter, with domestic formulations and specialty launches driving growth despite US pricing pressure. Companies like Sun Pharmaceuticals and Lupin are likely to lead the way, driven by their specialty businesses. Sun Pharma's revenue is expected to grow in the\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89851"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89851\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}